Press coverage about Kala Pharmaceuticals (NASDAQ:KALA) has trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Kala Pharmaceuticals earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned headlines about the company an impact score of 44.6587389795431 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Kala Pharmaceuticals (NASDAQ KALA) traded down $0.49 during midday trading on Friday, reaching $14.93. The company had a trading volume of 441,745 shares, compared to its average volume of 493,980. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.00 and a current ratio of 11.00. Kala Pharmaceuticals has a one year low of $11.81 and a one year high of $26.75.

Kala Pharmaceuticals (NASDAQ:KALA) last posted its quarterly earnings results on Tuesday, November 7th. The company reported ($0.56) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.14). equities analysts forecast that Kala Pharmaceuticals will post -2.22 earnings per share for the current year.

A number of research analysts recently issued reports on the company. BidaskClub upgraded Kala Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, January 13th. JPMorgan Chase & Co. set a $35.00 price objective on Kala Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, November 19th. Wedbush reiterated a “buy” rating and set a $46.00 price objective on shares of Kala Pharmaceuticals in a research note on Thursday, November 30th. Wells Fargo & Co reiterated a “buy” rating on shares of Kala Pharmaceuticals in a research note on Friday, January 5th. Finally, Zacks Investment Research downgraded Kala Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $36.80.

In other Kala Pharmaceuticals news, major shareholder Orbimed Advisors Llc purchased 240,484 shares of the stock in a transaction that occurred on Friday, January 12th. The shares were bought at an average cost of $13.28 per share, with a total value of $3,193,627.52. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

ILLEGAL ACTIVITY NOTICE: This article was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.

Insider Buying and Selling by Quarter for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with's FREE daily email newsletter.